CTI Capital
VC Fund
Quebec, Canada
CTI Capital is a venture capital fund that invests in development-stage, Canadian life sciences companies.
- Total investments:
- 7
- Last investment:
- Lead investor:
- 29%
Last updated:
For AI agents: llms.txt
Industries CTI Capital invests in
BiotechnologyMedicalB2BGeneticsHardware
Stages CTI Capital invests in
Funding RoundSeries ASeries BSeries CVenture - Series Unknown
Countries CTI Capital invests in
CanadaSpainSingapore
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Investment Focus
Industry
- Biotechnology 3 (43%)
- Medical 2 (29%)
- B2B 1 (14%)
- Genetics 1 (14%)
- Hardware 1 (14%)
Stage
- Funding Round 2 (29%)
- Series A 1 (14%)
- Series B 1 (14%)
- Series C 1 (14%)
- Venture - Series Unknown 1 (14%)
Country
- Canada 3 (43%)
- Spain 1 (14%)
- Singapore 1 (14%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Shermaine Tilley
Partner
|
Partner | Total investments: 9 | Find email | |
|
Bernard Casimir
Registered Representative
|
Registered Representative | Total investments: 0 | Find email | |
|
François Soto
Research Analyst, Equity Market.
|
Research Analyst, Equity Market. | Total investments: 0 | Find email | |
|
Guylaine Couillard
Administrative Assistant
|
Administrative Assistant | Total investments: 0 | Find email | |
Ivan Greenstein
Institutional Representative, Fixed Income
|
Institutional Representative, Fixed Income | Total investments: 0 | Find email | |
| See all 8 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Wattio
|
Wattio develops and sells a range of gadgets and software forming a high end Smart Home solution. Characteristics:Secure technology platform entirely developed in house: the Company masters all hard-, firm- & software involved in its solution to ensure flexibility Scalable and flexible Gateway: the Linux minicomputer allows toexpand the solution by connecting additional new gadgets or integrating third party hardware devicesComplete (“all-in-one”) multi-sector approach: the solution centralizes every aspect of home management (Electricity/energy, comfort, security and care) in only one solutionSimplicity of usage and coherent design: all products are easily installable and self-explanatory, representing a cool & consistent look to integrate nicely within the users’ home decorationHigh product quality at an affordable price: locally designed and manufactured products including only high quality electronics contribute to a high perceived quality at a very competitive price | $192.6K / Venture - Series Unknown / Jan 18, 2022 | |
Xagenic
|
Xagenic Inc., a Toronto, Canada-based molecular diagnostics company developing new technology for decentralized, rapid diagnostic testing, and a true point-of-care platform. Our aim is to enable on-demand, near-patient molecular testing, empowering clinicians in making treatment decisions for their patients at the time of the first consultation.This will dramatically improve patient care and reduce health care costs. Xagenic has adapted this technology to permit rapid, enzyme-free detection of nucleic acids from clinical samples.We are commercializing a simple and fully automated technology platform that will enable widespread decentralized diagnostic testing to be performed outside of clinical laboratories. Our team is developing infectious disease tests that will allow the detection of a variety of analytes in situations where rapid test turnaround will provide clinically actionable results. | $25.5M / Series B / Jul 14, 2014 | |
|
Xagenic
|
Xagenic Inc., a Toronto, Canada-based molecular diagnostics company developing new technology for decentralized, rapid diagnostic testing, and a true point-of-care platform. Our aim is to enable on-demand, near-patient molecular testing, empowering clinicians in making treatment decisions for their patients at the time of the first consultation.This will dramatically improve patient care and reduce health care costs. Xagenic has adapted this technology to permit rapid, enzyme-free detection of nucleic acids from clinical samples.We are commercializing a simple and fully automated technology platform that will enable widespread decentralized diagnostic testing to be performed outside of clinical laboratories. Our team is developing infectious disease tests that will allow the detection of a variety of analytes in situations where rapid test turnaround will provide clinically actionable results. | $10M / Series A / Jan 30, 2012 | |
Zymeworks
|
Zymeworks is a computational biotechnology company focused on optimizing therapeutic antibodies and other protein-based therapeutics. The company is committed to developing best-in-class protein therapeutics for the treatment of cancer, autoimmune, and inflammatory diseases.Zymeworks' approach combines proprietary molecular modeling andsimulation software with high-performance computing to create an environment for in silico experimentation and predictive protein optimization. Using this approach Zymeworks has developed multiple platform technologies to advance the field of biologics drug discovery and optimization.It was founded in 2004 and headquartered in Vancouver, British Columbia. | $8.1M / Sep 22, 2011 | |
Enobia Pharma
|
Enobia develops therapies to treat serious genetic bone disorders for which there are no approved treatments. | $50M / Series C / Aug 10, 2009 | |
|
Zymeworks
|
Zymeworks is a computational biotechnology company focused on optimizing therapeutic antibodies and other protein-based therapeutics. The company is committed to developing best-in-class protein therapeutics for the treatment of cancer, autoimmune, and inflammatory diseases.Zymeworks' approach combines proprietary molecular modeling andsimulation software with high-performance computing to create an environment for in silico experimentation and predictive protein optimization. Using this approach Zymeworks has developed multiple platform technologies to advance the field of biologics drug discovery and optimization.It was founded in 2004 and headquartered in Vancouver, British Columbia. | $3.2M / Jun 29, 2009 | |
BeXcom
|
BeXcom, a privately held corporation founded in 1996, operates a global network of eCommerce hubs in the world's major trading zones. This global transaction infrastructure enables companies and exchanges to conduct business electronically locally or with multiple trading partners around the world.BeXcom's Commerce Service Providermodel provides and maintains all the required hardware and software to operate centralized B2B eCommerce solutions for their users. By building on the BeXcom infrastructure, supply chains, vertical markets and market makers can quickly implement or dramatically extend their eCommerce capabilities to cover the complete range of purchasing processes, from RFQ to settlement.BeXcom is the first company to integrate global financial, logistics, and certificate authority services into a global eCommerce infrastructure, ensuring all transactions are safe, secure, and verifiable.BeXcom helps their customers streamline business processes, reduce costs, expand markets and add value to their business by delivering the full potential of B2B eCommerce. | $75M / Mar 31, 2000 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
Enterprise Investors
77,348 investors
Health Care Investors
43,014 investors
Hardware Investors
40,144 investors
Biotech Investors
21,775 investors
Biotechnology Investors
19,370 investors
Medical Investors
18,848 investors
B2B Investors
9,977 investors
Enterprise VC Funds
49,693 investors
Health Care VC Funds
32,370 investors
FAQ
What does CTI Capital invest in?
CTI Capital invests primarily in Biotechnology, Medical and B2B startups, most often at Funding Round and Series A stage. Most of the 7 investments tracked by Shizune back companies in Canada. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact CTI Capital?
Public channels for CTI Capital include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at CTI Capital?
The team at CTI Capital includes Shermaine Tilley (Partner), Bernard Casimir (Registered Representative) and François Soto (Research Analyst, Equity Market.), among 8 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
